Episode Details
Back to EpisodesEylea HD Approved for RVO and Extended Dosing
Published 6 months ago
Description
Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease.
Learn more about your ad choices. Visit megaphone.fm/adchoices